Details

Autor(en) / Beteiligte

• BARTSCH, Detlef K
• SINA-FREY, Mercedes
• HAHN, Stephan A
• ROTHMUND, Matthias
• RIEDER, Harald
• FERNANDEZ-CRUZ, L
• LANG, Sven
• WILD, Anja
• GERDES, Berthold
• BARTH, Peter
• KRESS, Ralf
• GRUTZMANN, Robert
• COLOMBO-BENKMANN, Mario
• ZIEGLER, Andreas

Titel

CDKN2A germline mutations in Familial Pancreatic Cancer

Ist Teil von

• Annals of surgery, 2002-12, Vol.236 (6), p.730-737

Ort / Verlag

Hagerstown, MD: Lippincott

Erscheinungsjahr

2002

Quelle

MEDLINE

Beschreibungen/Notizen

• To evaluate the prevalence of mutations in the CDKN2A gene encoding p16 and p14 in familial pancreatic cancer (FPC). The genetic basis of FPC is still widely unknown. Recently, it has been shown that germline mutations in the p16 tumor suppressor gene can predispose to pancreatic cancer. The presence of p14 germline mutations has yet not been determined in this setting. Eighteen families with at least two first-degree relatives with histologically confirmed pancreatic cancer and five families with at least one patient with pancreatic cancer and another first-degree relative with malignant melanoma of the German National Case Collection for Familial Pancreatic Cancer were analyzed for CDKN2A germline mutations including p16 and p14 by direct DNA sequencing. All participating family members were genetically counseled and evaluated by a three-generation pedigree. None of 18 FPC families without malignant melanoma revealed p16 mutations, compared to 2 of 5 families with pancreatic cancer and melanoma. Truncating p16 germline mutations Q50X and E119X were identified in the affected patients of pancreatic cancer plus melanoma families. None of the 23 families revealed p14 germline mutations. CDKN2A germline mutations are rare in FPC families. However, these data provide further evidence for a pancreatic cancer-melanoma syndrome associated with CDKN2A germline mutations affecting p16. Thus, all members of families with combined occurrence of pancreatic cancer and melanoma should be counseled and offered screening for p16 mutations to identify high-risk family members who should be enrolled in a clinical screening program.